Share on StockTwits

NxStage Medical (NASDAQ:NXTM) released its earnings data on Thursday. The company reported ($0.12) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.01, Analyst Ratings.Net reports. The company had revenue of $74.10 million for the quarter, compared to the consensus estimate of $70.52 million. During the same quarter last year, the company posted ($0.06) earnings per share. NxStage Medical’s revenue was up 13.3% compared to the same quarter last year.

A number of analysts have recently weighed in on NXTM shares. Analysts at Zacks upgraded shares of NxStage Medical from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 2nd. They now have a $15.60 price target on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research note on Friday, May 9th. They now have a $19.00 price target on the stock, down previously from $21.00. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $16.92.

Shares of NxStage Medical (NASDAQ:NXTM) traded up 9.85% during mid-day trading on Thursday, hitting $14.50. The stock had a trading volume of 147,134 shares. NxStage Medical has a 52 week low of $8.77 and a 52 week high of $15.00. The stock has a 50-day moving average of $13.76 and a 200-day moving average of $13.27. The company’s market cap is $890.5 million.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 3,550 shares of the company’s stock on the open market in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $13.50, for a total value of $47,925.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.